uniQure N.V. (Nasdaq: QURE) priced an upsized underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, according to a press release from the gene therapy company.

The offering is expected to generate approximately $225 million in gross proceeds before underwriting discounts, commissions, and other expenses. All shares in the offering are being sold by uniQure.

The company has also granted underwriters a 30-day option to purchase up to 741,758 additional ordinary shares at the offering price, less underwriting discounts and commissions.

The offering is expected to close on or about June 25, 2026, subject to customary closing conditions.

Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets are serving as joint bookrunning managers. H.C. Wainwright & Co. is acting as lead manager.

The securities are being offered under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on January 7, 2025.